Over the past month I have been speaking with a biotech founders and pharmaceutical leaders adjusting to US centric hiring rather than global.
Their board was pushing for US-based hires.
And with the geopolitical landscape shifting — tariffs, nationalist policy, and a stronger push for domestic manufacturing under the new Trump administration — it’s understandable why pharma companies are looking to build in the US.
But then we reviewed the commercial and leadership hiring costs.
Every critical role in the US came in 50–200% higher than the equivalent role in the UK or Western Europe.
Same calibre.
Same track record.
Same experience developing, manufacturing or selling.
Just a dramatically different price.
That conversation changed the direction of their hiring strategy.
Because smart, global businesses are starting to realise something:
This isn’t about offshoring to low-cost regions or chasing labour arbitrage.
This is about accessing mature, experienced pharmaceutical leadership in the UK and Europe — regions with deep global regulatory expertise, global market exposure, and global commercial relationships.
High-calibre pharma talent doesn’t sit on the bench for long.
And right now, there’s a window where companies can secure more experience for less cost, without compromising capability or proximity to the US market.
At Allerton Bishop, we’re seeing the smart and curious hire talent they may not have accessed previously.
In high-stakes industries like pharma and biologics, hiring isn’t just about location — it’s about leverage and true expertise.
So when leaders ask where the advantage is in 2025, my answer is simple:
It’s about balance. Mature Talent. Cost Saving. Political Saavy.
If you’re hiring and want to explore how the geo-political shifts can work to your advantage. I would be happy to walk you through what we’re seeing.
Allerton Bishop, we offer creative, cost-effective solutions that don’t compromise on service or quality.
👉 Contact Allerton Bishop
👉 Schedule a Discovery Call